Cagrilintide 20mg — Vial Spec, Reconstitution Math & COA

Overview: Specifications and Target Applications for the 20mg Vial

A 20mg vial of Cagrilintide contains 20 milligrams of sterile, lyophilized, synthetic acylated amylin analog powder, engineered specifically for high-volume in vitro assays and extensive preclinical animal models. This high-mass unit is selected primarily by academic institutions, contract research organizations (CROs), and industrial pharmaceutical laboratories seeking to minimize batch-to-batch variance across extended testing timelines or large assay cohorts.

While standard catalog configurations often feature lower mass options such as 5mg or 10mg units on our cagrilintide product page, high-capacity 20mg specifications are routinely deployed for automated liquid handling platforms, continuous perfusion models, or multi-week preclinical animal studies. Providing 20,000 micrograms of active peptide mass per vessel, this format reduces physical storage footprints in lab freezers and decreases the cumulative cost of repeated reconstitutions.

If a specific research protocol requires immediate dispatch of alternative fill sizes or customized bulk lots beyond our active catalog inventory, researchers can explore our complete all peptides catalog or consult our institutional team for specialized batch manufacturing options.

Molecular Structure and Mechanism of Action

Cagrilintide is a long-acting, non-selective human amylin receptor agonist (AMYR1, AMYR2, and AMYR3) that also demonstrates potent binding affinity at the calcitonin receptor (CTR). Structurally, it is an acylated peptide featuring a lipid moiety attached via a hydrophilic spacer to its primary amino acid chain, designed to extend serum half-life by binding reversibly to endogenous albumin in animal models.

Preclinical rodent models indicate that activation of central amylin receptors in the area postrema and nucleus of the solitary tract leads to sustained reduction in voluntary nutrient intake, altered gastric emptying kinetics, and improved peripheral lipid utilization. In vitro binding studies confirm that Cagrilintide exhibits full intrinsic activity at all three human amylin receptor subtypes when co-expressed with receptor activity-modifying proteins (RAMP1, RAMP2, and RAMP3).

Because Cagrilintide functions along pathways distinct from classical incretin mimetics, researchers frequently examine its activity both independently and in co-administration paradigms. Detailed mechanistic documentation and citation indexes are available within our research library hub.

Reconstitution Mathematics for 20mg Cagrilintide Vials

Accurate reconstitution of high-mass peptide vials requires careful volumetric calculation to achieve target working concentrations without exceeding solubility thresholds. Because 20mg represents a dense solid mass of lyophilized cake (inclusive of counter-ions and lyoprotectants such as mannitol or trehalose), final solution displacement must be accounted for during analytical preparation.

When reconstituting a 20mg vial with standard laboratory diluents such as Bacteriostatic Water (0.9% benzyl alcohol) or Sterile Normal Saline (0.9% NaCl), the resulting concentration varies directly with added liquid volume:

1.0 mL Diluent Addition: Yields a final concentration of 20.0 mg/mL (20.0 µg/µL or 20,000 µg/mL). This highly concentrated stock solution is ideal for micro-dosing platforms, microfluidic chips, or automated high-density assay plates where minimal fluid volumes are required. 2.0 mL Diluent Addition: Yields a final concentration of 10.0 mg/mL (10.0 µg/µL or 10,000 µg/mL). This standard stock strength allows straightforward volumetric pipetting across rodent assay cohorts. 3.0 mL Diluent Addition: Yields a final concentration of 6.67 mg/mL (6.67 µg/µL or 6,667 µg/mL). This lower concentration mitigates volumetric error when manually metering sub-milligram doses with standard laboratory micropipettes.

To verify exact mathematical conversions for varying diluent volumes or target microgram deliveries, researchers should utilize our interactive reconstitution calculator prior to fluid handling.

Aliquot Strategy and Freeze-Thaw Prevention

Reconstituting a 20mg vial creates a substantial working stock solution that must be handled with precise physical care. Repeated freeze-thaw cycles cause cryo-concentration, mechanical shear, and localized pH fluctuations that trigger peptide aggregation or cleavage of the acylated lipid side chain.

To preserve structural integrity following initial reconstitution, researchers should divide the primary stock solution into single-use micro-aliquots using sterile, low-binding polypropylene microcentrifuge tubes. Aliquots should be sized according to single-day or single-assay consumption limits, rapidly frozen in liquid nitrogen or an ethanol/dry-ice bath, and immediately transferred to a dedicated -80°C ultralow freezer.

When preparing micro-aliquots, ensure air headspace in each vial is minimized to prevent oxidative degradation, and never store reconstituted liquid stocks in standard frost-free freezers, which utilize temperature cycling that compromises peptide stability.

Lot-Matched COA and Quality Control Protocol

Every production lot of Cagrilintide supplied by PX1 Research undergoes stringent analytical testing in an independent, ISO 17025 accredited laboratory to verify identity, purity, mass balance, and bio-burden prior to distribution. Each 20mg vial is directly linked to its lot-specific Certificate of Analysis.

Analytical metrics provided on every lot-matched COA include:

High-Performance Liquid Chromatography (HPLC): Confirms chromatographic purity exceeding 99.0%, ensuring the absence of structural truncations, deletion sequences, or uncoupled lipid chains. Mass Spectrometry (MS): Electrospray ionization mass spectrometry (ESI-MS) confirms exact molecular weight matching theoretical sequence limits. Endotoxin Testing: Verified via Limulus Amebocyte Lysate (LAL) assay, ensuring endotoxin levels remain strictly below < 0.01 EU/mg to prevent inflammatory interference in cell culture or in vivo research. Residual Solvent & Heavy Metal Screening: Confirms complete elimination of organic synthesis solvents (e.g., trifluoroacetic acid, acetonitrile) and trace heavy metals.

All testing documentation is accessible online by cross-referencing the lot number printed on the physical vial label.

Selecting the Optimal Fill Size: 5mg vs 10mg vs 20mg

Choosing between a 5mg, 10mg, or 20mg Cagrilintide vial configuration depends primarily on the experimental scale, duration, and stability constraints of the planned assay. Reconstituted peptides gradually undergo chemical degradation in aqueous media even under refrigeration (2°C to 8°C), making vial selection an essential variable in experimental design.

A 5mg or 10mg vial is optimal for short-term pilot studies, small-animal exploratory cohorts, or localized cell culture experiments where the reconstituted liquid will be completely consumed within 14 to 21 days. Using smaller fill sizes reduces the risk of long-term aqueous degradation and minimizes product waste if experimental protocols change.

Conversely, a 20mg vial is superior for automated continuous infusion studies, high-throughput screening libraries, or extended longitudinal rodent models requiring consistent dosing across multiple weeks from a single uniform manufacturing batch. When high-volume routine purchasing is required, laboratories may also evaluate our wholesale accounts program to establish predictable inventory supply chains.

Comparative Analysis: Cagrilintide vs. Related Metabolic Agonists

In preclinical metabolic research, Cagrilintide occupies a distinct mechanistic niche compared to GLP-1 and GIP receptor agonists. While classical incretin mimetics act primarily on pancreatic beta cells and enteric vagal afferents, Cagrilintide's dual amylin/calcitonin receptor agonism targets central satiation centers directly, making it a powerful tool for comparative metabolic mapping.

When designed into multi-arm comparative studies, Cagrilintide is frequently evaluated alongside single, dual, or triple-receptor incretin compounds. For instance, researchers comparing dual receptor class actions often benchmark Cagrilintide against the GLP-1 receptor agonist semaglutide, the dual GIP/GLP-1 receptor agonist tirzepatide, or the triple GIP/GLP-1/Glucagon receptor agonist retatrutide.

In vitro data show that co-activating the amylin/calcitonin pathway alongside GLP-1/GIP pathways yields synergistic reductions in energy intake and synergistic improvements in glycemic control in animal models without causing overlapping receptor desensitization or competitive binding inhibition.

Storage, Handling, and Reconstitution Protocol

To maintain optimal peptide stability and ensure reproducibility across scientific trials, strict physical handling and environmental controls must be maintained from receipt through final assay delivery.

Lyophilized Powder Storage: Upon receipt, sealed vials containing dry lyophilized peptide should be stored at -20°C for short-to-medium term storage, or at -80°C for extended archival storage up to 24 months. Protect vials from direct light exposure.

Reconstitution Protocol: Allow the lyophilized vial to equilibrate to room temperature (20°C to 25°C) before introducing diluent to prevent condensation inside the glass vessel. Using a sterile syringe, slowly direct the diluent down the glass inner wall of the vial rather than shooting liquid directly onto the lyophilized cake. Gently swirl the vial in a circular motion until completely dissolved. Never shake or vortex the vial vigorously, as mechanical agitation can induce protein denaturation and foam formation.

Post-Reconstitution Storage: Reconstituted liquid stock solutions stored at 2°C to 8°C should be used within 14 to 28 days depending on diluent antimicrobial agents. Aliquoted freezer stocks at -80°C remain stable for up to 6 months.